Tag Archives: Staci R Stevens

Cardiopulmonary exercise test methodology for assessing exertion intolerance in ME/CFS

Posted on 09/07/2018 by wames

Cardiopulmonary Exercise Test Methodology for Assessing Exertion Intolerance in ME/CFS by Staci Stevens, Chris Snell, Jared Stevens, Betsy Keller and J Mark VanNess in Frontiers in Pediatrics, 4 September 2018 Background: Concise methodological directions for administration of serial cardiopulmonary exercise testing (CPET) … Continue reading →

Posted in News | Tagged , , , , , , , , , | Comments Off on Cardiopulmonary exercise test methodology for assessing exertion intolerance in ME/CFS

Checking our blind spots: current status of research evidence summaries in ME/CFS

Posted on 07/23/2018 by wames

Checking our blind spots: current status of research evidence summaries in ME/CFS, by Todd E Davenport, Staci R Stevens, J Mark VanNess, Jared Stevens, Christopher R Snell in British Journal of Sports Medicine, July 2018 Editorial: The evidence-based practice (EBP) … Continue reading →

Posted in News | Tagged , , , , , , , , | Comments Off on Checking our blind spots: current status of research evidence summaries in ME/CFS

Characteristics of CFS/ME sub-group who respond to Rintatolimod (Ampligen)

Posted on 09/29/2015 by wames

Research abstract: Background: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a debilitating disease of unknown pathogenesis consisting of  a variety of flu-like symptoms including severe fatigue. Initial analysis of the use of rintatolimod (Poly I: Poly C12U), a selective TLR3 agonist, … Continue reading →

Posted in News | Tagged , , , , , , , , , , , , , , | Comments Off on Characteristics of CFS/ME sub-group who respond to Rintatolimod (Ampligen)